The litigation seeks to hold pharmaceutical companies accountable for this alleged pattern through Ozempic gastroparesis lawsuits and similar claims, demanding compensation for medical expenses, lost wages, pain and suffering, and permanent disabilities caused by injuries patients allege they would have avoided had they received adequate warnings
Employers should consider requiring documented diagnoses, evidence-based prior authorization, and stepped therapy, plus lifestyle programs before approving GLP-1s for weight loss to curb long-term spend
Wegovy (semaglutide injection, Novo Nordisk), Zepbound (tirzepatide injection, Eli Lilly), Saxenda (liraglutide injection, Novo Nordisk), and oral Wegovy (semaglutide tablets, approved December 2025)
GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials
An obesity lab panel is designed to catch any underlying health issues that could affect treatment safety or effectiveness
Of those, more than 65 percent reached a BMI of below 30 within 80 weeks, which no longer classified them as having obesity
